Genprex’s Response to COVID-19 and its Business Operations
April 29, 2020
At Genprex, the health and well-being of the communities we serve, including those with cancer and diabetes, is our top priority.
While our country and world navigate through the short and long-term impact of COVID-19, Genprex continues to monitor the latest news about the virus as well as the guidance issued by federal, state and local officials.
During this period of economic and global uncertainty, we remain steadfast in our mission to develop potentially life-changing gene technologies for patients with cancer and diabetes. Our unwavering commitment to our mission continues to be our guiding responsibility, now more than ever.
Our small but nimble team is able work virtually or remotely, meaning that we haven’t lost pace or slowed our workload. In fact, much of our team has worked virtually since the company was founded. Furthermore, in the past month we have strengthened and expanded our leadership team with the appointment of three accomplished executives, and we have bolstered our Board of Directors with three biotechnology and pharmaceutical leaders.
With the on-boarding of new executives and Board of Director members, combined with our significantly strengthened balance sheet, our business operations are continuing as normal. We remain completely committed to executing on our plans and strategy we have set forth for 2020 and into next year.
This pandemic has highlighted the need for modern medicine to save lives. We are working to bring our potentially life-changing gene technologies to those with cancer and diabetes, because we truly believe our therapies can address these medical needs and save lives. We thank you for your continued support in Genprex, and we hope that you and your loved ones remain safe during this pandemic.